🔎 Trials Near Me

Home › Schizophrenia

Schizophrenia clinical trials recruiting in the U.S.

105 studies for Schizophrenia are recruiting participants at sites across the United States.

Schizophrenia is a serious brain illness that can include hearing voices that aren't there and thinking others are trying to hurt them.

Cities with the most studies

By state

Recently updated studies

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

RecruitingPhase 3
Ages 13 to 17 · All sexes · Updated Nov 12, 2026 · NCT07288567

A Study to Evaluate the Effect of KarXT on Urological Safety

RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Nov 10, 2026 · NCT07221877

Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia

RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Nov 10, 2026 · NCT07592169

A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia

RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Nov 9, 2026 · NCT07908680

Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1

RecruitingHealthy volunteers welcome
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT07853807

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3

RecruitingHealthy volunteers welcome
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT07900893

REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

Recruiting
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT07006935

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07379827

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Oct 30, 2026 · NCT07686263

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Oct 30, 2026 · NCT07680946

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

Recruiting
Ages 18 to 60 · All sexes · Updated Oct 28, 2026 · NCT05389787

The Effects of Auditory Stimulation During Sleep on Brain Networks in Schizophrenia

RecruitingHealthy volunteers welcome
Ages 18 to 45 · All sexes · Updated Oct 20, 2026 · NCT06386588

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Oct 15, 2026 · NCT07459647

iTBS to Enhance Social Cognition in People With Psychosis

Recruiting
Ages 18 to 39 · All sexes · Updated Oct 8, 2026 · NCT06118268

A Study of Brenipatide in Adult Participants With Schizophrenia

RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Oct 7, 2026 · NCT07410507

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

RecruitingPhase 4
Ages 12 to 17 · All sexes · Updated Oct 1, 2026 · NCT05648591

Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls

RecruitingHealthy volunteers welcome
Ages 18 to 50 · All sexes · Updated Oct 1, 2026 · NCT07680114

Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy

Recruiting
Ages 18 to 65 · All sexes · Updated Sep 30, 2026 · NCT06835556

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07101094

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07227818

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07105098

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.